The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells.
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
07
2018
revised:
26
10
2018
accepted:
03
12
2018
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
29
3
2019
Statut:
epublish
Résumé
The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we investigated
Identifiants
pubmed: 30918522
doi: 10.1155/2019/6254269
pmc: PMC6409035
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6254269Subventions
Organisme : NCI NIH HHS
ID : SC1 CA173069
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC1 GM121287
Pays : United States
Références
Mitochondrion. 2007 Feb-Apr;7(1-2):39-44
pubmed: 17280879
J Biol Chem. 2009 May 22;284(21):14165-76
pubmed: 19339246
Cancer Res. 2009 May 15;69(10):4225-34
pubmed: 19435925
J Oncol. 2010;2010:396286
pubmed: 20445750
PLoS One. 2011 Feb 28;6(2):e17234
pubmed: 21386904
Clin Drug Investig. 2011;31(6):435-8
pubmed: 21401215
J Vis Exp. 2011 Mar 13;(49):null
pubmed: 21445039
PLoS One. 2012;7(5):e37045
pubmed: 22666341
Mol Cancer Ther. 2012 Aug;11(8):1672-82
pubmed: 22689530
Clin Toxicol (Phila). 2014 Feb;52(2):129-35
pubmed: 24283301
J Transl Med. 2014 May 16;12:131
pubmed: 24885034
Nucl Med Mol Imaging. 2014 Mar;48(1):16-25
pubmed: 24900134
Biochem J. 2014 Sep 15;462(3):475-87
pubmed: 25017630
Cancer Med. 2014 Dec;3(6):1467-76
pubmed: 25220156
Oncotarget. 2014 Dec 30;5(24):12877-90
pubmed: 25375092
Cell Biochem Biophys. 2015 Mar;71(2):1207-13
pubmed: 25403159
Cell Adh Migr. 2015;9(4):265-76
pubmed: 25482627
Int J Endocrinol. 2014;2014:717198
pubmed: 25587274
Breast Cancer (Dove Med Press). 2015 Aug 31;7:251-65
pubmed: 26355636
Cell Cycle. 2016;15(3):403-12
pubmed: 26709750
Oncotarget. 2016 Feb 2;7(5):6188-200
pubmed: 26717043
Stem Cell Res Ther. 2015 Dec 30;6:262
pubmed: 26718286
Mol Med Rep. 2016 Mar;13(3):2590-6
pubmed: 26847819
Target Oncol. 2016 Aug;11(4):447-67
pubmed: 26864078
Stem Cells Int. 2016;2016:5603135
pubmed: 26880969
Oncotarget. 2016 May 10;7(19):28235-46
pubmed: 27058422
Oncol Lett. 2016 Apr;11(4):2792-2800
pubmed: 27073554
Cancer Chemother Pharmacol. 2016 Jul;78(1):13-26
pubmed: 27118574
Oncotarget. 2016 Jun 21;7(25):38500-38512
pubmed: 27223262
J Cell Physiol. 2017 Aug;232(8):2033-2043
pubmed: 27504932
J Cell Physiol. 2017 Sep;232(9):2497-2507
pubmed: 27662422
Biomed Pharmacother. 2016 Dec;84:1575-1584
pubmed: 27825799
Am J Transl Res. 2016 Nov 15;8(11):4812-4821
pubmed: 27904682
J Cell Physiol. 2017 Sep;232(9):2280-2286
pubmed: 27925198
J Exp Clin Cancer Res. 2017 Feb 13;36(1):28
pubmed: 28193239
Cell Death Discov. 2017 Feb 27;3:17009
pubmed: 28250972
Tumour Biol. 2017 Mar;39(3):1010428317694310
pubmed: 28351327
Stem Cells Int. 2017;2017:5987015
pubmed: 29201061